We are live on ! Find out more
CCM

Catalio Capital Management Portfolio holdings

AUM $479M
1-Year Est. Return 140.7%
This Fund
S&P 500
This Quarter Est. Return
+25.45%
1 Year Est. Return
+140.7%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$566M
AUM Growth
+$24.9M
Cap. Flow
-$80.8M
Cap. Flow %
-14.28%
Top 10 Hldgs %
51.19%
Holding
52
New
14
Increased
5
Reduced
20
Closed
7

Top Buys

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$35.2M
2
BMY icon
Bristol-Myers Squibb
BMY
+$31.2M
3
JNJ icon
Johnson & Johnson
JNJ
+$23.9M
4
EW icon
Edwards Lifesciences
EW
+$15.4M
5
MLYS icon
Mineralys Therapeutics
MLYS
+$13.3M

Top Sells

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$35.9M
2
BBIO icon
BridgeBio Pharma
BBIO
+$32.3M
3
LLY icon
Eli Lilly
LLY
+$30.1M
4
ISRG icon
Intuitive Surgical
ISRG
+$23.5M
5
NTRA icon
Natera
NTRA
+$18M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RNAM
51
DELISTED
Avidity Biosciences
RNAM
– –
-263,256
Closed -$11.5M
KYTX icon
52
Kyverna Therapeutics
KYTX
$484M
– –
-586,909
Closed -$3.52M
1 2
3

Similar funds

FFG
Frisch Financial Group Melville, New York $478M AUM 16.28% 1-Year Est. Return
MVP
Medina Value Partners Los Angeles, California $477M AUM 25.52% 1-Year Est. Return
DA
Dash Acquisitions Woodland Hills, California $480M AUM 4.07% 1-Year Est. Return
NQWM
Northwest Quadrant Wealth Management Bend, Oregon $481M AUM 13.55% 1-Year Est. Return
MAM
Morse Asset Management Darien, Connecticut $481M AUM 46% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
VIA
Vickerman Investment Advisors Spokane, Washington $476M AUM 12.21% 1-Year Est. Return
DE
Devon Energy Houston, Texas $476M AUM

Catalio Capital Management's Q4 2025 Portfolio in Review

As of Q4 2025, Catalio Capital Management held 52 positions worth $566M, up 4.6% from $541M the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Catalio Capital Management withdrew a net $80.8M in Q4 2025, closing 7 positions and reducing 20 holdings. Its most notable exit was AbbVie, an estimated $35.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Catalio Capital Management opened a new position in Gilead Sciences worth $35.5M.

  • Catalio Capital Management's largest Q4 2025 buy was Gilead Sciences: 289,312 shares worth $35.5M.
  • Catalio Capital Management added most to Boston Scientific in Q4 2025, an estimated $9.55M increase.
  • Catalio Capital Management's biggest Q4 2025 reduction was Eli Lilly, cutting an estimated $30.1M.
  • Catalio Capital Management fully exited AbbVie in Q4 2025, selling an estimated $35.9M.
  • Catalio Capital Management's ten largest holdings make up 51% of its $566M portfolio in Q4 2025.
  • Catalio Capital Management opened 14 new positions and closed 7 in Q4 2025.
  • Catalio Capital Management's portfolio value rose 4.6% quarter-over-quarter to $566M.

Based on Catalio Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.